MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318597 | Name: Quazepam

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Quazepam is indicated for the treatment of insomnia including sleep induction and sleep maintenance. Quazepam induces impairment of motor function and has hypnotic and anticonvulsant properties with less overdose potential than other benzodiazepines. Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture. Quazepam is unique amongst benzodiazepines in that it selectively targets the GABAA α1 subunit receptors which are responsible for inducing sleep. Its mechanism of action is very similar to zolpidem and zaleplon in its pharmacology and can successfully substitute for zolpidem and zaleplon in animal studies. Quazepam is discontinued.

Chemical Structure

Quazepam
Quazepam
CAS#36735-22-5

Theoretical Analysis

MedKoo Cat#: 318597

Name: Quazepam

CAS#: 36735-22-5

Chemical Formula: C17H11ClF4N2S

Exact Mass: 386.0268

Molecular Weight: 386.79

Elemental Analysis: C, 52.79; H, 2.87; Cl, 9.17; F, 19.65; N, 7.24; S, 8.29

Price and Availability

This product was removed for the commercial reasons.
Related CAS #
No Data
Synonym
Quazepam; Dormalin; Prosedar; Oniria; Quazium; Selepam; quazepam; Quiedorm; Sch 16134
IUPAC/Chemical Name
7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
InChi Key
IKMPWMZBZSAONZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2
SMILES Code
C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 386.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yamaguchi K, Goda T, Yamaki S, Ohno Y. Structural analysis of quazepam metabolites in bile by ion trap time-of-flight mass spectrometry. Forensic Sci Int. 2015 Nov;256:7-16. doi: 10.1016/j.forsciint.2015.07.016. Epub 2015 Jul 17. PubMed PMID: 26301753. 2: Zhou J, Yamaguchi K, Ohno Y. Quantitative analysis of quazepam and its metabolites in human blood, urine, and bile by liquid chromatography-tandem mass spectrometry. Forensic Sci Int. 2014 Aug;241:e5-12. doi: 10.1016/j.forsciint.2014.04.027. Epub 2014 May 5. PubMed PMID: 24856286. 3: Terada M, Shinozuka T, Hasegawa C, Tanaka E, Hayashida M, Ohno Y, Kurosaki K. Analysis of quazepam and its metabolites in human urine by gas chromatography-mass spectrometry: application to a forensic case. Forensic Sci Int. 2013 Apr 10;227(1-3):95-9. doi: 10.1016/j.forsciint.2012.11.017. Epub 2013 Jan 3. PubMed PMID: 23290298. 4: Nishiyama T, Yamashita K, Yokoyama T, Imoto A, Manabe M. Effects of quazepam as a preoperative night hypnotic: comparison with brotizolam. J Anesth. 2007;21(1):7-12. Epub 2007 Jan 30. PubMed PMID: 17285406. 5: Sugimoto K, Araki N, Ohmori M, Harada K, Cui Y, Tsuruoka S, Kawaguchi A, Fujimura A. Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15. Epub 2006 Jan 17. PubMed PMID: 16416305. 6: Kanda H, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Otani K. Interaction study between fluvoxamine and quazepam. J Clin Pharmacol. 2003 Dec;43(12):1392-7. PubMed PMID: 14615476. 7: Roth TG, Roehrs TA, Koshorek GL, Greenblatt DJ, Rosenthal LD. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol. 1997 Oct;17(5):401-6. PubMed PMID: 9315991. 8: Mendels J. Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatients. J Clin Psychiatry. 1994 Feb;55(2):60-5. PubMed PMID: 7915708. 9: Saletu B, Anderer P, Brandstätter N, Frey R, Grünberger J, Klösch G, Mandl M, Wetter T, Zeitlhofer J. Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam). Neuropsychobiology. 1994;29(2):69-90. PubMed PMID: 8170529. 10: Scharf MB. Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. J Clin Psychiatry. 1993 Jan;54(1):33-8. PubMed PMID: 8428895. 11: Mauri MC, Gianetti S, Pugnetti L, Altamura AC. Quazepam versus triazolam in patients with sleep disorders: a double-blind study. Int J Clin Pharmacol Res. 1993;13(3):173-7. PubMed PMID: 7901174. 12: Hilbert JM, Battista D. Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics. J Clin Psychiatry. 1991 Sep;52 Suppl:21-6. Review. PubMed PMID: 1680120. 13: Quazepam: a new hypnotic. Med Lett Drugs Ther. 1990 Apr 20;32(816):39-40. PubMed PMID: 1970112. 14: Blom MW, Bartel PR, de Sommers K, Van der Meyden CH, Becker PJ. The effects of alprazolam, quazepam and diazepam on saccadic eye movements, parameters of psychomotor function and the EEG. Fundam Clin Pharmacol. 1990;4(6):653-61. PubMed PMID: 1982881. 15: Giorgi O, Corda MG, Gritti I, Mariotti M, Ongini E, Biggio G. Binding sites for [3H]2-oxo-quazepam in the brain of the cat: evidence for heterogeneity of benzodiazepine recognition sites. Neuropharmacology. 1989 Jul;28(7):715-8. PubMed PMID: 2569691. 16: Schölermann K, Kazemian-Erdmann F, Schütz H. [Screening and detection of quazepam and its metabolites]. Arzneimittelforschung. 1989 May;39(5):556-9. German. PubMed PMID: 2569308. 17: Schaffler K, Kauert G, Wauschkuhn CH, Klausnitzer W. Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam. Arzneimittelforschung. 1989 Feb;39(2):276-83. PubMed PMID: 2567171. 18: Wettstein JG. Effects of the novel benzodiazepine agonist quazepam on suppressed behavior of monkeys. Eur J Pharmacol. 1988 Oct 11;155(1-2):19-25. PubMed PMID: 2907488. 19: Oelschläger H, Volke J, Linde HF, Fedai I, Schmidt W. [Drug analysis with polarographic methods. XXXII. Reasons for the anomalous current-voltage curves of quazepam [7-chloro-5-(2-fluoro-phenyl) -1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione]. Arch Pharm (Weinheim). 1988 Aug;321(8):457-62. German. PubMed PMID: 2906236. 20: Gupta SK, Ellinwood EH Jr. Liquid chromatographic assay and pharmacokinetics of quazepam and its metabolites following sublingual administration of quazepam. Pharm Res. 1988 Jun;5(6):365-8. PubMed PMID: 3244647.

View History

IAJD97

IAJD97

Featured